LivaNova PLC $LIVN Shares Sold by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC reduced its stake in LivaNova PLC by 3.6%, now holding approximately 269,476 shares valued at about $10.6 million.
• LivaNova has seen a positive trend in analyst ratings, with several upgrades, including an upgraded rating to "strong-buy" from Wall Street Zen and price targets ranging from $55.00 to $64.00.
• The company's recent quarterly earnings exceeded expectations, reporting $1.05 EPS against an anticipated $0.84, with revenues reaching $352.5 million.

Great Lakes Advisors LLC decreased its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 3.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 269,476 shares of the company's stock after selling 9,927 shares during the quarter. Great Lakes Advisors LLC owned about 0.49% of LivaNova worth $10,585,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of LIVN. UMB Bank n.a. raised its stake in shares of LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after purchasing an additional 647 shares in the last quarter. CWM LLC raised its stake in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after purchasing an additional 1,184 shares in the last quarter. Central Pacific Bank Trust Division raised its stake in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after purchasing an additional 290 shares in the last quarter. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of LivaNova during the fourth quarter valued at about $241,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of recent analyst reports. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Barclays lifted their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, LivaNova currently has a consensus rating of "Buy" and a consensus target price of $59.71.

LivaNova Price Performance

Shares of LivaNova stock opened at $58.32 on Tuesday. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The company's 50-day moving average price is $48.94 and its two-hundred day moving average price is $43.70. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $58.42. The stock has a market cap of $3.18 billion, a PE ratio of -14.99 and a beta of 0.96.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. LivaNova's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.93 earnings per share. As a group, sell-side analysts anticipate that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.